Third quarter revenue grew 35.8% year-over-year to RMB92.6 million (US$13.6 million); Operating income grew 37.8% year-over-year to RMB28.5 million (US$4.2 million); Company reiterates FY2009 revenue guidance
SHENYANG, China, Nov. 13 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the third quarter ended September 30, 2009.
Third Quarter 2009 Financial Highlights:
-- Total net revenues increased by 35.8% over the third quarter of 2008 to
RMB92.6 million (US$13.6 million).
-- Operating income increased by 37.8% over the third quarter of 2008 to
RMB28.5 million (US$4.2 million) on a GAAP basis, and increased by
34.7% over the third quarter of 2008 to RMB29.8 million (US$4.4
million) on a non-GAAP basis.
-- Net income increased by 1343.5% over the third quarter of 2008 to
RMB26.9 million (US$3.9 million) on a GAAP basis, and increased by
25.6% over the third quarter of 2008 to RMB28.2 million (US$4.1
million) on a non-GAAP basis.
-- Net income per American Depositary Share ("ADS") for the third quarter
of 2009 was RMB1.25 (US$0.18) compared with RMB0.09 (US$0.01) for the
third quarter of 2008 on a GAAP basis, and RMB1.31 (US$0.19) for the
third quarter of 2009 compared with RMB1.03 (US$0.15) for the third
quarter of 2008 on a non-GAAP basis.
First Nine Months 2009 Financial Highlights:
-- Total net revenues in the first nine months of 2009 increased by 32.5%
to RMB242.6 million (US$35.5 million) compared to RMB183.2 million
(US$27.0 million) in the first nine months of 2008.
-- Operating income increased by 48.6% over the first nine months of 2008
to RMB74.5 million (US$10.9 million) on a GAAP basis, and increased by
44.3% to RMB77.5 million (US$11.4 million) on a non-GAAP basis.
-- Net income increased by 70.2% over the first nine months of 2008 to
RMB69.8 million (US$10.2 million) on a GAAP basis, and increased by
19.0% over the first nine months of 2008 to RMB75.8 million (US$11.1
million) on a non-GAAP basis.
-- Net income per ADS on a fully-diluted basis for the first nine months
of 2009 was RMB3.24 (US$0.47) compared with RMB1.89 (US$0.28) for the
first nine months of 2008 on a GAAP basis, and RMB3.52 (US$0.52)
compared with RMB2.93 (US$0.43) for the first nine months of 2008 on a
non-GAAP basis.
Third Quarter 2009 Business Highlights
-- EPIAO, the Company’s flagship injectable recombinant human
erythropoietin ("EPO") product, demonstrated strong growth with net
revenue from EPIAO in the third quarter of 2009 rising 32.6% to RMB56.6
million (US$8.3 million) compared to RMB42.7 million (US$6.3 million)
in the third quarter of 2008.
-- Net revenues for TPIAO, the Company’s novel recombinant human
thrombopoietin ("TPO") product, increased by 41.3% to RMB27.9 million
(US$4.1 million) in the third quarter of 2009, compared to RMB19.7
million (US$2.9 million) in the third quarter of 2008.
-- Construction of the new EPIAO and TPIAO manufacturing plant in Shenyang
remains on schedule for completion this year in preparation for
validation and certification next year.
-- Dr. Jing Lou, chief executive officer of 3SBio, commented:
"Overall, the business is performing as expected with a strong set of
results this quarter and we reiterate our full-year guidance of
US$43-45 million. Construction of our new plant remains on schedule and
we look forward to moving to validation and certification next year. We
continued to develop our product pipeline and will update the market
when we have reached significant milestones in the approval process."
Three months ended September 30, 2009 Unaudited Financial Results
Net revenues. Net revenues increased by 35.8% to RMB92.6 million (US$13.6 million) for the third quarter of 2009 from RMB68.2 million (US$10.0 million) for the same period in 2008. This increase was largely due to continued strength from EPIAO and TPIAO products, which increased by 32.6% and 41.3%, respectively, over the same period in 2008. TPIAO remained 3SBio’s second largest revenue contributor in the quarter, accounting for 30.1% of total net revenues. Export sales declined by 6.4% to RMB2.3 million (US$0.3 million), and revenues from our in-licensed IV Iron Sucrose supplement rose 113.7% to RMB3.7 million (US$0.5 million).
Gross profit. As a result of continued sales growth from key products, GAAP gross profit for the third quarter of 2009 increased by 38.3% to RMB86.1 million (US$12.6 million) from RMB62.2 million (US$9.2 million) for the same period in 2008. GAAP gross margin increased by 1.7% to 93.0% for the third quarter of 2009 from 91.3% for the same period in 2008.
Operating expenses. GAAP operating expenses were RMB57.6 million (US$8.4 million) for the third quarter of 2009, an increase of 38.6% from GAAP operating expenses of RMB41.5 million (US$6.1 million) for the same period in 2008. Non-GAAP operating expenses were RMB56.4 million (US$8.3 million) for the third quarter of 2009, an increase of 40.3% from non-GAAP operating expenses of RMB40.2 million (US$5.9 million) for the same period in 2008. The increase in operating expenses was largely driven by higher R&D expenses, particularly at the early stage of the pipeline.
-- Research and development ("R&D") costs. GAAP R&D costs for the third
quarter of 2009 were RMB7.6 million (US$1.1 million), or 8.2% of net
revenue, compared to RMB4.2 million (US$0.6 million), or 6.2% of net
revenue for the same period in 2008.
-- Sales, marketing and distribution expense. GAAP sales, marketing and
distribution expenses for the third quarter of 2009 were RMB41.6
million (US$6.1 million), or 44.9% of net revenue, compared to RMB29.3
million (US$4.3 million), or 42.9% of net revenue, for the same period
in 2008. The increase was primarily attributable to higher sales
activities in general and continued investment in building the TPIAO
and EPIAO brands.
-- General and administrative expenses. GAAP general and administrative
expenses for the third quarter of 2009 were RMB8.4 million (US$1.2
million), representing an increase of 4.6% from general and
administrative expenses of RMB8.0 million (US$1.2 million) for the same
period in 2008. This marked a decline to 9.1% of net revenue for the
third quarter of 2009, compared to 11.8% of net revenue for the third
quarter of 2008.
Operating income. GAAP operating income was RMB28.5 million (US$4.2 million) for the third quarter of 2009, an increase of 37.8% from operating income of RMB20.7 million (US$3.1 million) for the same period in 2008.
Non-GAAP operating income for the third quarter of 2009 grew by 34.7% to RMB29.8 million (US$4.4 million), compared to RMB22.1 million (US$3.3 million) in the third quarter of 2008.
GAAP operating margin for the third quarter of 2009 was 30.8% as compared to 30.4% for the same period in 2008. Non-GAAP operating margin was 32.2% for the third quarter of 2009, as compared to 32.4% in the same period in 2008.
Interest income. The Company recorded net interest income of RMB2.6 million (US$0.4 million) for the third quarter of 2009, compared to RMB5.5 million (US$0.8 million) for the same period in 2008.
Net income. GAAP net income was RMB26.9 million (US$3.9 million) for the third quarter of 2009, 1343.5% higher than net income of RMB1.9 million (US$0.3 million) for the same period in 2008. GAAP net income per ADS on a fully-diluted basis for the third quarter of 2009 increased to RMB1.25 (US$0.18) from RMB0.09 (US$0.01) for the same period in 2008. GAAP net margin for the third quarter of 2009 was 29.1% as compared to 2.7% for the same period in 2008.
Non-GAAP net income for the third quarter of 2009 was RMB28.2 million (US$4.1 million), 25.6% higher than non-GAAP net income of RMB22.4 million (US$3.3 million) for the same period in 2008. Non-GAAP net income per ADS on a fully diluted basis for the third quarter of 2009 increased to RMB1.31 (US$0.19) from RMB1.03 (US$0.15) for the same period in 2008. Non-GAAP net margin for the third quarter of 2009 was 30.4% as compared to 32.9% for the same period in 2008.
Nine months ended September 30, 2009 Unaudited Financial Results
Net revenues. Net revenues for the first nine months of 2009 increased by 32.5% to RMB242.6 million (US$35.5 million), from RMB183.2 million (US$27.0 million) for the same period in 2008. The increase was primarily attributable to increased sales from our EPIAO and TPIAO products, underpinned by continued strong demand in the oncology and nephrology markets.
Net revenues from EPIAO for the first nine months of 2009 increased by 30.6% to RMB150.5 million (US$22.1 million) from RMB115.2 million (US$17.0 million) for same period in 2008. Net revenues from TPIAO in the first nine months of 2009 increased by 34.4% to RMB68.8 million (US$10.1 million) from RMB51.2 million (US$7.5 million) for the same period in 2008. In addition, revenue from our export business was RMB9.1 million (US$1.3 million), representing an increase of 27.9% over the first nine months of 2008, while revenue from our in-licensed IV Iron Sucrose supplement was RMB8.7 million (US$1.3 million), representing an increase of 67.7% over the first nine months of 2008.
Gross profit. GAAP gross profit for the first nine months of 2009 increased by 33.9% to RMB223.7 million (US$32.8 million) from RMB167.1 million (US$24.6 million) for the same period in 2008. GAAP gross margin increased by 1.0% to 92.2% for the first nine month months of 2009 from 91.2% for the same period in 2008.
Operating income. For the first nine months ended September 30, 2009, GAAP operating income increased by 48.6% to RMB74.5 million (US$10.9 million), compared to RMB50.1 million (US$7.4 million) for the same period in 2008. Non-GAAP operating income increased by 44.3% to RMB77.5 million (US$11.4 million), compared to RMB53.7 million (US$7.9 million) for the same period in 2008.
GAAP operating margin for the first nine months ended September 30, 2009 was 30.7% as compared to 27.3% for the nine months ended September 30, 2008. Non-GAAP operating margin was 31.9% for the nine months ended September 30, 2009, as compared to 29.3% in the same period in 2008.
Net income. GAAP net income for the first nine months of 2009 increased by 70.2% to RMB69.8 million (US$10.2 million) compared with RMB41.0 million (US$6.0 million) for the same period in 2008. GAAP net margin for the first nine months ended September 30, 2009 was 28.8% as compared to 22.4% for the same period in 2008. GAAP net income per ADS on a fully diluted basis for the first nine months of 2009 increased to RMB3.24 (US$0.47) from RMB1.89 (US$0.28) for the same period in 2008.
Non-GAAP net income for the first nine months of 2009 increased by 19.0% to RMB75.8 million (US$11.1 million) compared with RMB63.7 million (US$9.4 million) for the same period in 2008. Non-GAAP net margin for the first nine months ended September 30, 2009 was 31.2% as compared to 34.8% for the same period in 2008. Non-GAAP net income per ADS for the first nine months of 2009 increased to RMB3.52 (US$0.52) from RMB2.93 (US$0.43) for the same period in 2008.
Cash and cash equivalents / Time deposits. 3SBio had positive operating cash flows of RMB61.6 million (US$9.0 million) for the first nine months of 2009, and as of September 30, 2009 retained a strong balance sheet with cash, cash equivalents and time deposits of RMB731.5 million (US$107.2 million), a 0.2% decrease from RMB733.0 million (US$107.4 million) as of December 31, 2008.
2009 Full Year Guidance
Based on current market conditions and visibility provided during the third quarter, the Company reiterates its total net revenue target for the full year of 2009 of between US$43 million to US$45 million, resulting in a year-over-year increase of approximately 21% to 26%.
Conference Call
3SBio’s senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on November 13, 2009 to discuss its 2009 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:
Conference ID: 38479039
Local dial-in:
China - landline 800-819-0121
China - mobile 400-620-8038
International toll-free dial-in:
Hong Kong 800930346
United Kingdom 080-8234-6646
United States 1-866-519-4004
International toll dial-in: 65-6735-7955
Replay- Conference ID: 38479039
A telephone replay will be available two hours after the call until
November 20, 2009, at:
International dial-in: +61-2-8235-5000
United States dial-in: 1-866-214-5335
Webcast
A live webcast of the conference will be available on the investor relations page of 3SBio’s website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/yf93ntk . A replay of the webcast will be available within one hour after the conclusion of the call.
Non-GAAP Financial Measures: Reconciliation of GAAP to Non-GAAP
To supplement the Company’s financial information presented in accordance with general accepted accounting principles ("GAAP"), the Company has utilized some non-GAAP financial measures to provide investors and management with supplemental measures that facilitate comparisons of operating performance and trends with prior and future operating performance, and that may not otherwise be apparent on a GAAP basis. These non-GAAP financial measures include non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP net income per share, and non-GAAP net income per ADS. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principals, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company’s results of operations in conjunction with the corresponding GAAP measures. Please see the attached reconciliation of GAAP to non-GAAP for an explanation of the amounts excluded to arrive at non-GAAP financial measures for the three-month periods ended September 30, 2009 and September 30, 2008 and for the nine month periods ended September 30, 2009 and September 30, 2008.
Statement Regarding Unaudited Financial Information
The unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in our annual report on Form 20-F for the year ending December 31, 2009. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.
Currency Convenience Translation
For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.8262 to US$1.00, the noon buying rate for US dollars in effect on September 30, 2009 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. A rate of 6.7899 was used for comparative purposes as of September 30, 2008.
About 3SBio Inc.
3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com
Safe Harbor Statement
Certain statements in the disclosures of 3SBio, Inc. (the "Company" or "3SBio") for the third quarter of fiscal 2009 ("Disclosures") that are not purely historical in nature may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to the third quarter of fiscal 2009.
These forward-looking statements address activities, events, conditions, or developments that we currently expect or anticipate may occur in the future, and include, but may not be limited to, discussions and statements regarding revenue guidance, product development, timing of plant construction completion, testing and certification, impact of the government policies and regulations, regulatory approval process, production capacity, capital expense estimate, future operations, investment portfolio management, and future strategies. Forward-looking statements can be identified by such terminology as "believe," "expect," "plans," "strategy," "potential", "prospects," "forecast," "estimate," "project," "anticipate," "aim," "will" or "would", "may" or "might", and words, phrases, expressions, and usages of similar meaning or substance or the negative of such words, phrases, expressions and usages.
Forward-looking statements are based on management’s current assumptions, beliefs, expectations, and projections, in light of the information currently available to it, and actual results, performances, or achievements could differ materially from those implied or expressed by the forward-looking statements. Among the factors that could cause 3SBio’s actual results to differ from what the Company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; the completion of 3SBio’s ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio’s new products and uses; 3SBio’s ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China.
For additional information on factors identified above and other risk factors, uncertainties and assumptions that may affect 3SBio’s business, financial conditions and results of operations, please refer to the Company’s filings with the Securities and Exchange Commission at www.sec.gov, and, in particular, "Introduction - Cautionary Statement concerning Forward Looking Statements", Item 3.D "Risk Factors", Item 5. "Operating and Financial Review and Prospects", and other applicable discussions in 3SBio’s annual report on Form 20-F for the year ended December 31, 2008.
All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on the 3SBio website or otherwise. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, subsequent events or otherwise, after the date of this press release.
For more information, please contact:
Investor Contacts
Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: +86-24-2581-1820
Email: ir@3SBio.com
Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: +852-8191-6991
Email: ir@3SBio.com
3SBio Inc. and subsidiaries
Consolidated balance sheets
(expressed in thousands)
December 31 September 30 September 30
2008 2009 2009
RMB RMB US$
Assets (unaudited) (unaudited)
Current assets
Cash and cash equivalents 439,237 334,196 48,958
Time deposits with financial
institutions 293,809 397,306 58,203
Accounts receivable, less allowance
for doubtful accounts: December 31,
2008 - RMB4,503; September 30, 2009
- RMB3,439 (US$504) 48,927 71,495 10,474
Notes receivable 24,840 30,278 4,436
Inventories 7,748 12,130 1,777
Prepaid expenses and other
receivables 8,249 9,260 1,357
Deferred tax assets 1,802 2,581 378
Total current assets 824,612 857,246 125,583
Available-for-sale securities 26,700 14,682 2,151
Property, plant and equipment, net 78,185 139,263 20,401
Lease prepayments 8,894 8,629 1,264
Non-current deposits 8,521 15,596 2,285
Intangible assets, net 5,225 4,400 645
Deferred tax assets 781 106 16
Total assets 952,918 1,039,922 152,345
Liabilities
Current liabilities
Accounts payable 1,939 3,062 449
Deferred grant income 374 374 55
Accrued expenses and other payables 25,273 35,569 5,211
Income tax payable 1,256 3,323 487
Other current liabilities 57 -- --
Total current liabilities 28,899 42,328 6,202
Deferred grant income 3,152 2,871 421
Other liabilities 472 -- --
Total liabilities 32,523 45,199 6,623
Commitments and contingencies -- -- --
Shareholders’ equity
Share capital - ordinary shares
US$0.0001 par value, 500,000,000
shares authorized, 150,575,955 and
150,635,189 issued and outstanding
as of December 31, 2008 and
September 30, 2009, respectively 121 121 18
Additional paid-in capital 908,377 911,562 133,539
Accumulated other comprehensive loss (102,126) (100,768) (14,762)
Retained earnings 114,023 183,808 26,927
Total shareholders’ equity 920,395 994,723 145,722
Total liabilities and shareholders’
equity 952,918 1,039,922 152,345
3SBio Inc. and subsidiaries
Consolidated statements of income
(expressed in thousands, except per share,
per ADS and other share and ADS data)
Three Months Ended September 30, 2009
Adjust-
GAAP GAAP ment Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
(unaudited)(unaudited)(unaudited)(unaudited)(unaudited)
Net Revenues:
EPIAO 56,558 8,285 -- 56,558 8,285
TPIAO 27,893 4,086 -- 27,893 4,086
Intefen 1,633 239 -- 1,633 239
Inleusin 473 69 -- 473 69
Iron 3,703 542 -- 3,703 542
Export 2,282 334 -- 2,282 334
Others 21 3 -- 21 3
Total net revenues 92,563 13,558 -- 92,563 13,558
Cost of revenues (6,473) (948) 123 (1) (6,350) (930)
Gross profit 86,090 12,610 -- 86,213 12,628
Operating expenses
Research and
development costs (7,616) (1,116) 121 (1) (7,495) (1,098)
Sales, marketing
and distribution
expenses (41,551) (6,087) 169 (1) (41,382) (6,062)
General and
administrative
expenses (8,386) (1,229) 820 (1) (7,566) (1,108)
Total operating
expenses (57,553) (8,432) (56,443) (8,268)
Operating income 28,537 4,178 29,770 4,360
Other income/
(expenses), net
Interest income 2,637 386 -- 2,637 386
Grant income 94 14 -- 94 14
Others 124 18 -- 124 18
Total other income,
net 2,855 418 2,855 418
Income before
income tax
expense 31,392 4,596 32,625 4,778
Income tax expense (4,471) (655) -- (4,471) (655)
Net income 26,921 3,941 28,154 4,123
Net income per
share:
Basic and diluted 0.18 0.03 0.19 0.03
Basic weighted
average number
of shares 150,621,780 150,621,780 150,621,780 150,621,780
outstanding
Effect of
dilutive
potential
shares 608,488 608,488 608,488 608,488
Diluted
weighted
average
number of
shares
outstanding 151,230,268 151,230,268 151,230,268 151,230,268
Net income
per ADS:
Basic and
diluted 1.25 0.18 1.31 0.19
Basic weighted
average number
of ADSs
outstanding 21,517,397 21,517,397 21,517,397 21,517,397
Effect of
dilutive
potential
ADSs 86,927 86,927 86,927 86,927
Diluted
weighted
average
number of
ADSs
Outstanding 21,604,324 21,604,324 21,604,324 21,604,324
3SBio Inc. and subsidiaries
Consolidated statements of income
(expressed in thousands, except per share,
per ADS and other share and ADS data)
Three Months Ended September 30, 2008
Adjust-
GAAP GAAP ment Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
(unaudited)(unaudited)(unaudited)(unaudited)(unaudited)
Net Revenues:
EPIAO 42,650 6,282 -- 42,650 6,282
TPIAO 19,736 2,907 -- 19,736 2,907
Intefen 1,398 206 -- 1,398 206
Inleusin 186 27 -- 186 27
Iron 1,733 255 -- 1,733 255
Export 2,439 359 -- 2,439 359
Others 8 1 -- 8 1
Total net
revenues 68,150 10,037 68,150 10,037
Cost of revenues (5,923) (872) 111 (1) (5,812) (856)
Gross profit 62,227 9,165 62,338 9,181
Operating
expenses
Research and
development
costs (4,242) (625) 154 (1) (4,088) (602)
Sales, marketing
and distribution
expenses (29,260) (4,309) 297 (1) (28,963) (4,266)
General and
administrative
expenses (8,018) (1,181) 838 (1) (7,180) (1,057)
Total operating
expenses (41,520) (6,115) (40,231) (5,925)
Operating income 20,707 3,050 22,107 3,256
Other income/
(expenses), net
Interest income 5,461 804 -- 5,461 804
Grant income 94 14 -- 94 14
Impairment loss
on available-
for-sale
securities (19,144) (2,819) 19,144 (2) -- --
Others (1,058) (156) -- (1,058) (156)
Total other
income, net (14,647) (2,157) 4,497 662
Income before
income tax
expense and
minority
interests 6,060 893 26,604 3,918
Income tax
expense (4,272) (629) -- (4,272) (629)
Income before
minority
interests 1,788 264 22,332 3,289
Minority
interests, net
of tax 77 11 -- 77 11
Net income 1,865 275 22,409 3,300
Net income per
share:
Basic and diluted 0.01 0.00 0.15 0.02
Basic weighted
average number
of shares
outstanding 151,862,722 151,862,722 151,862,722 151,862,722
Effect of
dilutive
potential
shares 7,222 7,222 7,222 7,222
Diluted
weighted
average
number of
shares
outstanding 151,869,944 151,869,944 151,869,944 151,869,944
Net income per
ADS:
Basic and
diluted 0.09 0.01 1.03 0.15
Basic weighted
average number
of ADSs
outstanding 21,694,675 21,694,675 21,694,675 21,694,675
Effect of
dilutive
potential ADSs 1,032 1,032 1,032 1,032
Diluted weighted
average number
of ADSs
outstanding 21,695,707 21,695,707 21,695,707 21,695,707
3SBio Inc. and subsidiaries
Consolidated statements of income
(expressed in thousands, except per share,
per ADS and other share and ADS data)
Nine Months Ended September 30, 2009
Adjust-
GAAP GAAP ment Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
(unaudited)(unaudited) (unaudited) (unaudited)(unaudited)
Net Revenues:
EPIAO 150,549 22,055 -- 150,549 22,055
TPIAO 68,820 10,082 -- 68,820 10,082
Intefen 4,188 614 -- 4,188 614
Inleusin 1,166 171 -- 1,166 171
Iron 8,700 1,275 -- 8,700 1,275
Export 9,133 1,338 -- 9,133 1,338
Others 88 13 -- 88 13
Total net
revenues 242,644 35,548 -- 242,644 35,548
Cost of
revenues (18,990) (2,782) 365 (1) (18,625) (2,728)
Gross profit 223,654 32,766 -- 224,019 32,820
Operating expenses
Research and
development
costs (14,325) (2,099) 366 (1) (13,959) (2,045)
Sales, marketing
and distribution
expenses (110,742) (16,223) 471 (1) (110,271) (16,154)
General and
administrative
expenses (24,137) (3,536) 1,808 (1) (22,329) (3,271)
Total operating
expenses (149,204) (21,858) (146,559) (21,470)
Operating income 74,450 10,908 77,460 11,350
Other income/
(expenses), net
Interest income 9,163 1,342 -- 9,163 1,342
Grant income 281 41 -- 281 41
Disposal gain on
available-for-sale
securities 1,611 236 (1,611) (2) -- --
Impairment loss on
available-for-sale
securities (4,624) (677) 4,624 (2) -- --
Others 1,463 214 -- 1,463 214
Total other income,
net 7,894 1,156 10,907 1,597
Income before
income
tax expense 82,344 12,064 -- 88,367 12,947
Income tax
expense (12,559) (1,840) -- (12,559) (1,840)
Net income 69,785 10,224 75,808 11,107
Net income
per share:
Basic and
diluted 0.46 0.07 0.50 0.07
Basic weighted
Average number
of shares
outstanding 150,598,359 150,598,359 150,598,359 150,598,359
Effect of
dilutive
potential
shares 114,151 114,151 114,151 114,151
Diluted
weighted
average
number of
shares
outstanding 150,712,510 150,712,510 150,712,510 150,712,510
Net income
per ADS:
Basic and
diluted 3.24 0.47 3.52 0.52
Basic weighted
average
number
of ADSs
outstanding 21,514,051 21,514,051 21,514,051 21,514,051
Effect of
dilutive
potential ADSs 16,307 16,307 16,307 16,307
Diluted
weighted
average
number of
ADSs
outstanding 21,530,358 21,530,358 21,530,358 21,530,358
3SBio Inc. and subsidiaries
Consolidated statements of income
(expressed in thousands, except per share,
per ADS and other share and ADS data)
Nine Months Ended September 30, 2008
Adjust-
GAAP GAAP ment Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
(unaudited)(unaudited)(unaudited)(unaudited)(unaudited)
Net Revenues:
EPIAO 115,244 16,972 -- 115,244 16,972
TPIAO 51,212 7,542 -- 51,212 7,542
Intefen 3,790 558 -- 3,790 558
Inleusin 564 83 -- 564 83
Iron 5,188 764 -- 5,188 764
Export 7,141 1,052 -- 7,141 1,052
Others 42 6 -- 42 6
Total net
revenues 183,181 26,977 183,181 26,977
Cost of
revenues (16,119) (2,374) 260 (1) (15,859) (2,336)
Gross profit 167,062 24,603 167,322 24,641
Operating expenses
Research and
development
costs (10,038) (1,478) 359 (1) (9,679) (1,425)
Sales, marketing
and distribution
expenses (81,441) (11,994) 691 (1) (80,750) (11,893)
General and
administrative
expenses (25,498) (3,756) 2,271 (1) (23,227) (3,421)
Total operating
expenses (116,977) (17,228) (113,656) (16,739)
Operating income 50,085 7,375 53,666 7,902
Other income/
(expenses), net
Interest income 18,037 2,656 -- 18,037 2,656
Grant income 281 41 -- 281 41
Impairment loss on
available-for-sale
securities (19,144) (2,819) 19,144 (2) -- --
Others 2,761 407 -- 2,761 407
Total other income,
net 1,935 285 21,079 3,104
Income before
income
tax expense
and minority
interests 52,020 7,660 74,745 11,006
Income tax
expense (11,192) (1,648) -- (11,192) (1,648)
Income before
minority
interests 40,828 6,012 63,553 9,358
Minority
interests,
net of tax 172 25 -- 172 25
Net income 41,000 6,037 63,725 9,383
Net income per
share:
Basic and diluted 0.27 0.04 0.42 0.06
Basic weighted
average number
of shares
outstanding 152,019,769 152,019,769 152,019,769 152,019,769
Effect of
dilutive
potential
shares 7,222 7,222 7,222 7,222
Diluted
weighted
average
number of
shares
outstanding 152,026,991 152,026,991 152,026,991 152,026,991
Net income
per ADS:
Basic and
diluted 1.89 0.28 2.93 0.43
Basic weighted
average
number of
ADSs
outstanding 21,717,110 21,717,110 21,717,110 21,717,110
Effect of
dilutive
potential
ADSs 1,032 1,032 1,032 1,032
Diluted
weighted
average
number of
ADSs
outstanding 21,718,142 21,718,142 21,718,142 21,718,142
Notes to reconciliation of our GAAP statements of income to our adjusted
statements of income:
(1) To exclude share-based compensation expenses from its non-GAAP
measures primarily because they are non-cash expenses that the
Company does not believe are reflective of ongoing operating
results.
(2) To exclude the impact caused by the impairment and/or disposal
losses on available-for-sale securities from its non-GAAP measures,
which is one-off in nature.
